BUSINESS

• Daiichi Sankyo CEO Sees High Odds of Success for AML Drug Quizartinib
  May 13, 2016

• Daiichi Sankyo Sees 7.3% Sales Rise, but Girding for FY2016 Dip on Olmesartan Cliff
  May 13, 2016

• Kissei Ditches Constipation Drug KWA-0711, Turns to Other Products for GI Entry
  May 13, 2016

• Nichi-Iko to Develop 3 Biosimilars for Global Market, Aims to Enter as Global Top-10 Generic Maker within 3 Years
  May 13, 2016

• Santen’s FY2015 Profits Zoom on Sale of RA Business
  May 13, 2016

• Astellas Unveils List of Approval Hopefuls in FY2016
  May 12, 2016

• Astellas Looking at Japan Filing of Romosozumab by March 2017
  May 12, 2016

• Under New Name, Ocata Positioned as R&D Hub for Regenerative Medicine, Ophthalmology: Astellas
  May 12, 2016

• Sumitomo Dainippon’s Sales Cross 400 Billion Yen as Latuda Becomes Blockbuster in N. America
  May 12, 2016

• Shionogi Scores Record Operating Profit as Royalties Spike
  May 12, 2016

• Mitsubishi Tanabe’s Sales Rise on Royalty, Upfront Revenues
  May 12, 2016

• Baxalta Sues Chugai over Hemophilia A Drug Patent
  May 12, 2016

• Ono Delivers Record Sales on Buoyant Opdivo, FY2016 Outlook Tops 250 Billion Yen
  May 12, 2016

• Astellas Logs Record Earnings on Bullish Xtandi in FY2015
  May 12, 2016

• Entyvio on Track to Rake in US$2 Billion in FY2018, Ninlaro Eyed as Next Big Seller
  May 11, 2016

• Takeda Drops Diabetic Nephropathy Drug amid Change in R&D Strategy
  May 11, 2016

• Takeda Enjoys Higher Revenues and Profits as Entyvio Sales Triple
  May 11, 2016

• Meiji Seika Pharma Jettisons BPH Treatment
  May 11, 2016

• AZ Set to Double Japan Sales by 2020 on Cancer Meds, No Patent Cliff in Sight: Local Pres. Baertschi
  May 11, 2016

• Taiho Establishes Venture Capital Unit in US to Invest in Field of Oncology
  May 11, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 472
• 473
• 474
• 475
• 476
• 477
• 478
• 479
• 480
• …
• Next ›
• 最終 »